Journal article
Pharmacokinetics of cefoperazone in normal subjects and patients with hepatosplenic schistosomiasis
Journal of antimicrobial chemotherapy, v 12(4), pp 407-410
Oct 1983
PMID: 6643335
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
The pharmacokinetics of cefoperazone were studied and compared in four normal subjects and six patients with hepatosplenic schistosomiasis (HSS) with mild liver disease but marked portal hypertension. All subjects received a 2 g intravenous infusion of cefoperazone over 15 min. Although most pharmacokinetic parameters did not differ significantly between normal subjects and patients with HSS, the serum β half-life of cefoperazone was longer in patients with HSS compared to normal subjects (3.0 h vs. 1.7 h). This demonstrates only mild impairment of excretion of cefoperazone in patients with HSS.
Metrics
Details
- Title
- Pharmacokinetics of cefoperazone in normal subjects and patients with hepatosplenic schistosomiasis
- Creators
- Jerome A. Boscia - Drexel UniversityOksana M. Korzeniowski - Drexel UniversityWilliam D. Kobasa - Drexel UniversityHeonir Rocha - University of Bahia Medical SchoolSalvadore, Bahia, BrazilMatthew E. Levison - Drexel UniversityDonald Kaye - Drexel University
- Publication Details
- Journal of antimicrobial chemotherapy, v 12(4), pp 407-410
- Publisher
- Oxford University Press
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Medicine (Graduate)
- Web of Science ID
- WOS:A1983RP21300015
- Scopus ID
- 2-s2.0-0021079883
- Other Identifier
- 991019184200804721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Infectious Diseases
- Microbiology
- Pharmacology & Pharmacy